Spondyloarthritis & psoriatic arthritis
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis
Authors' conclusion
There is a potential disconnect between objective measures of inflammation and clinical outcome responses in patients with axSpA.
Study context
- Population
- Patients with active axial spondyloarthritis (axSpA) treated with certolizumab pegol (CZP) for 12 weeks
- Participants
- 136 patients
- Comparison
- r-axSpA vs nr-axSpA
- r-axSpAn = 76
- nr-axSpAn = 60
Methodological detailsexploratory, mixed model with repeated measures, two independent MRI readers, four reading campaigns pooled
- Exploratory
- Mixed model with repeated measures
- Two independent MRI readers, four reading campaigns pooled
Primary result
As reported in the abstract
12 weeks
- CRP reduced by ≥50%
- 136/136 [100.0%]
- ASspiMRI-a Berlin score reduced by ≥50%
- 73/136 [53.7%]
- SPARCC SIJ score reduced by ≥50%
- 71/136 [52.2%]
- BASDAI ≥50% reduction
- 64/136 [47.1%]
- ASDAS ≥50% reduction
- 66/136 [48.5%]
Original publication
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis. RMD Open. Published 28 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →